Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target Lead asset LX2006 is an ...
The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...
Some cats wobble, fall over constantly, and generally have no control over their movements. These cats live with the ...
Larimar Therapeutics ( ($LRMR) ) has provided an update. On November 10, 2025, Larimar Therapeutics announced an updated slide presentation ...
Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Solid Biosciences is conducting a study ...
Lexeo Therapeutics Inc. feels like it’s in a faster lane to a BLA for its Friedreich ataxia cardiomyopathy gene therapy after talking with the U.S. FDA. The agency told Lexeo that LX-2006 could be on ...
The backpack, known as the Gyropack, uses gyroscopic technology similar to that used in space stations or large satellites to maintain orientation in space. An innovative backpack, incorporating ...
Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA). In May ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback